Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK

Overview of attention for article published in PharmacoEconomics, May 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 2 Facebook pages

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 96 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 30 Jun 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.